key: cord-0004250-ieaklip5
authors: Shimamura, Yoshinosuke; Maeda, Takuto; Nishizawa, Keitaro; Ogawa, Yayoi; Takizawa, Hideki
title: Gastrointestinal bleeding is associated with renal prognosis in adult patients with IgA vasculitis with nephritis
date: 2019-10-15
journal: J Gen Fam Med
DOI: 10.1002/jgf2.285
sha: a7fedb32092ab3b67b2bf0b59335d6fbb882ab3d
doc_id: 4250
cord_uid: ieaklip5

BACKGROUND: Although the prediction of renal prognosis in patients with IgA vasculitis with nephritis (IgAVN) is important, the association between gastrointestinal bleeding (GIB) and its renal prognosis is unknown. This study investigated the effect of GIB on the progression to end‐stage kidney disease (ESKD) in patients with IgAVN. METHODS: We compared the clinicopathological findings at diagnosis, therapy, and clinical outcomes between 10 patients with GIB and 20 patients without GIB in 30 patients with IgAVN aged ≥18 years at the renal biopsy. The primary outcome was the incidence of ESKD. Secondary outcomes included clinical remission and all‐cause mortality. The outcomes and factors affecting the progression to ESKD were evaluated using the Kaplan‐Meier method with log‐rank test and Cox proportional hazards models. RESULTS: End‐stage kidney disease, clinical remission, and deaths from any related cause occurred in 6, 17, and 2 patients, respectively. In Kaplan‐Meier analyses, the GIB group showed a higher incidence of ESKD (50% vs 5%, P = .003) and a lower incidence of clinical remission (20% vs 75%, P = .003). Although the numbers were not statistically significant, this group tended to have a greater number of deaths than the non‐GIB group (7% vs 0%, P = .07). In a multivariable Cox model adjusted for hypertension and urinary proteinuria, GIB could not demonstrate a significant association with ESKD (hazard ratio, 4.51; 95% confidence interval, 0.39‐52.7; P = .23). CONCLUSION: IgAVN with GIB has worse renal outcome, but GIB does not have a statistically significant association with progression to ESKD.

in 20-to 29-year-old and 60-to 69-year-old individuals. 1, [3] [4] [5] [6] [7] IgAV is often involved with the kidneys, which is called IgAV with nephritis (IgAVN): 30%-50% of children and 45%-85% of adult cases. 1, 3 They also reported that adult patients with IgAVN have a higher rate of renal involvement and, thus, a greater risk of progression to endstage kidney disease (ESKD) than children. [6] [7] [8] [9] Clinical findings at the time of diagnosis indicated advanced age, baseline renal function, lower serum albumin levels, hypertension, and proteinuria to be risk factors for ESKD. 7, 8, [10] [11] [12] A multicenter retrospective cohort study, using the Japan Renal Biopsy Registry, demonstrated that age older than 65 years and hypoalbuminemia were the independent prognostic factors for a decline in renal function. 13 Although gastrointestinal bleeding (GIB) because of various causes, such as hemorrhagic erosions and ulcers, is common, 9, 14, 15 its impact on renal prognosis in patients with IgAVN remains uncertain. In addition, patients with IgAV often visit primary care physicians with common complaints such as palpable purpura, arthritis, and gastrointestinal symptoms, so that study on the prognosis of IgAV is relevant for general physicians. Therefore, we conducted this retrospective cohort study to investigate the effects of GIB on renal prognosis and mortality; furthermore, we examined the factors that affect the progression to ESKD in adult patients with IgAVN. 16 We performed a chart review of patients with IgAVN using the Teine Keijinkai Renal Biopsy Registry (TK-RBR) at Teine Keijinkai Medical Center and gathered information between January 1, 2000, and December 31, 2018.

The main measurement of exposure in this study was GIB one month before and after the diagnosis of IgAVN, which had been defined as endoscopically proven GIB, melena, and/or hematemesis. Baseline characteristics, as well as laboratory and pathological data, were evaluated by physicians in charge of each patient in every individual case at the time of the initial evaluation. Baseline characteristics of the patients included age, gender, body mass index (body weight

[kg]/height 2 [m 2 ]), systolic and diastolic blood pressure, presence/ absence of edema, comorbidities (hypertension, diabetes mellitus, liver diseases, endometriosis, uterine fibroids), and prescribed medications (aspirin, warfarin, nonsteroidal anti-inflammatory drugs).

Hypertension was defined as a state in which systolic blood pressure was greater than 140 mm Hg and/or diastolic blood pressure was greater than 90 mm Hg, and antihypertensive drugs were being used as treatment before diagnosis of IgAVN. Diabetes mellitus was defined as the condition in which HbA1c was greater than 6.5% The primary outcome of interest that was measured here was the incidence of ESKD, which was indicated by an eGFR less than 15 mL/min/1.73 m 2 or the initiation of renal replacement therapy, including hemodialysis, peritoneal dialysis, or renal transplant within 5 years of diagnosis. The incidence of ESKD was ascertained from each patient's medical records prepared by the physicians in charge of them. Secondary outcomes recorded here were time to death from any cause and time to clinical remission, which was defined as the disappearance of hematuria and proteinuria. The disappearance of hematuria was defined as a condition with fewer than 5/ high-power field of erythrocytes in sediment or (−) to (±) in dipstick tests. The disappearance of proteinuria was defined by the presence of less than a total of 0.3 g/d of protein in urine samples collected over a 24-hour period or urine protein/urine creatinine ratio of less than 0.3, when recorded from spot urine or (−) to (±) dipstick tests.

The follow-up period was defined as the time from the initial diagnosis to (a) incidence of ESKD or (b) the last follow-up visit, whichever came first. Cases in which death occurred before ESKD incidence were not considered for further analysis.

We used Student's t test or the Wilcoxon rank-sum test to compare continuous variables based on their distributions, and Fisher's exact test to compare the proportions of categorical variables between the GIB and non-GIB groups. The normality of the variance for each continuous variable was analyzed using the Shapiro-Wilk W test.

The ISKDC classification was compared between the groups using single-factor analysis of variance (ANOVA).

We used the Kaplan-Meier method to estimate incidences of ESKD, clinical remission, and death; the records thus obtained were compared by using the log-rank tests. Data were censored on December 31, 2018. Patients who were lost till the time of follow-up were removed at the date of the last contact. Patients who were alive on December 31, 2018, were considered for analysis. We used Cox proportional hazards models to assess the association of GIB and several covariates with the incidence of ESKD; the results were expressed as hazard ratios (HR) with 95% confidence intervals (CI). All the independent variables included in univariable analyses were either categorical (coded as 0/1) or quantitative. Categorical variables included hypertension, RASi, endocapillary proliferation lesions (≥25%), steroid pulse therapy, and GIB. Quantitative variables included age, gender, urinary protein levels, eGFR, and serum red blood cell counts. Multivariable Cox analyses were applied to determine the relationship between the incidence of ESKD and GIB, as well as age, gender, hypertension, and urinary protein levels.

Variables included in the multivariable Cox analysis were selected based on previous studies and the results of the univariable analysis.

The sample size calculation was based upon the primary outcome, which was estimated to be 50% 17 in the GIB group and 20% 8, 10, 11, 18 in the non-GIB group. With a significance threshold of P = .05 in statistical analyses and 80% statistical power, the total sample size was calculated to be 80 after adjusting for 5% attrition, leaving 40 individuals in each group.

We have presented data on continuous variables as means with standard deviations (SD) or medians with associated interquartile ranges, while categorical variables are presented as numbers and percentages. We used the STATA software (version 15.1; StataCorp LLC) to perform statistical analyses. All the reported P-values are two-sided. We considered a P-value less than .05 to indicate statistical significance.

Among the 1085 eligible patients who were registered in the TK-RBR from January 1, 2000, to November 30, 2018, at the Teine Keijinkai Medical Center, 35 (3.4%) only the patients with IgAVN were included in this study. We excluded three patients who had not completed the one-month follow-up requirement and two patients who had missing data. The remaining 30 patients were included in further analyses.

Baseline clinicopathological characteristics are summarized in Table 1 .

Ten out of the 30 (33%) patients developed GIB. The median age of patients was 58 years, and the mean body mass index was 24 ± 4.3 kg/ m 2 . These statistics were comparable between the two groups (P = .059 and .81, respectively). As compared to the patients without GIB, patients with GIB had a higher prevalence of hypertension (70% vs 25%, P = .045), higher urinary protein levels (median [ The incidence of ESKD was significantly higher in the GIB group (five events, 50%) than in the non-GIB group (one event, 5%) (logrank test, P = .003) (Figure 1) . Additionally, the incidence of clinical remission was significantly lower in the GIB group (2 events, 20%) than in the non-GIB group (15 events, 75%) (log-rank test, P = .003) ( Figure 2) . A total of 2 (6.7%) deaths occurred, both in the GIB group as a result of hemorrhagic shock secondary to massive GIB.

However, the mortality rate was not significantly different between the two groups (log-rank test, P = .07).

As per the univariable analysis with Cox proportional hazards models ( 

with IgAVN and identified the factors that affect progression to ESKD. The results showed that patients who developed GIB were at a higher risk of ESKD with lower chances of clinical remission.

Although the relationship was not statistically significant, the patients with GIB tended to have more deaths than those without GIB. Although GIB is not independently associated with progression to ESKD with adjustment for covariates, our results suggest that assessment of GIB may be an effective method to identify patients with IgAVN who are at a high risk of ESKD.

The renal prognosis in adult patients with IgAVN was worse than that in children. 9 Previous studies have shown that it ranged from 9% to 27% because of substantial heterogeneity across studies, as well as limitations in study designs, patient populations, and definition of outcomes. 8, 10, 11, 18 A more recent study, using the Japan Renal Biopsy Registry, reported that the rate of decline in renal function (defined as a 50% increase in sCr from baseline or ESKD with renal replacement therapy) was 21.7% in Japanese patients with IgAVN. 13 In the present study, 20% of the patients reached ESKD in the 5-year follow-up period, comparable to results from the previous study. 18 Additionally, our results from the univariable analysis are in line with previous studies, demonstrating that urinary protein levels and hypertension are independent predictors of renal prognosis in patients with IgAVN. 10, 12, 18 We found out that patients with GIB are more likely to develop ESKD and less likely to reach clinical remission than those without GIB. This may be biologically plausible because GIB can cause anemia and subsequent hypo-oxygenation of the kidney, contributing to the development of ESKD. 19 Although GIB is one of the most acute life-threatening clinical manifestations, 9 only a few studies have reported an association between GIB and long-term progression to ESKD. A recent retrospective cohort study in France 6 reported that 43/137 (31%) patients with IgAV had GIB; however, they did not investigate the effect of GIB on the renal prognosis as we did in our study.

This study showed that the GIB group tended to have higher mortality than the non-GIB group, although the difference was not statistically significant between the groups. This may simply be because of the small sample size (type II error). Interestingly, we observed a relatively higher mortality of 2/30 (6.7%) patients than that reported in prior studies 6, 18 despite aggressive treatment with high-dose corticosteroids. The reasons remain unclear, but one possible explanation may be related to the inclusion of more severe cases in our study: The baseline sCr levels (1.21 ± 0.92 mg/ dL vs 0.91 ± 0.46 mg/dL) and the percentage of urine protein, that is, >3 g/d (32% vs 23%), were higher in our cohort than in the study performed using the Japan Renal Biopsy Registry. 13 We observed that GIB has a statistically significant association with ESKD with an adjustment for patients' age and gender; however, this result should be interpreted cautiously because it has a wide 95% confidence interval. Besides, GIB was not statistically significant after further adjustment with urinary protein levels and hypertension. Therefore, we could not conclude that GIB is an independent prognostic factor of ESKD in this study. Baseline characteristics, including age, BUN, and sCr, were not included in the multivariable analysis because they were similar in the two groups.

In addition, we did not include ISKDC classification and crescentic lesions in the Cox proportional hazards models because the performed. Despite these limitations, this was the first report to assess the association of gastrointestinal bleeding and renal prognosis in patients with IgAVN. Finally, we provide univariable analyses of ESKD, but we were unable to perform robust multivariable analyses for the outcome because of the limited number of events. 25 Prospective enrollment and multicenter data collection from the time of diagnosis would have been ideal but are difficult to achieve with a single-center study.

In conclusion, we performed a retrospective study on a patient cohort with IgAVN to compare the outcomes between the GIB and non-GIB groups. This study indicated that GIB is associated with the incidence of ESKD, as well as clinical remission in patients with

IgAVN, but it failed to be identified as an independent predictor of ESKD. Although these findings should be interpreted in the context of the small sample size, GIB may be a useful indicator for identification of patients with IgAVN at a high risk of ESKD.

We would like to thank Editage (www.edita ge.jp) for English language editing.

The authors have stated explicitly that there are no conflicts of interest in connection with this article. 

Yoshinosuke Shimamura https://orcid.org/0000-0003-0278-6900

revised International Chapel Hill Consensus Conference Nomenclature of Vasculitis

Differences in clinical manifestations and outcomes between adult and child patients with Henoch-Schönlein purpura

Clinical manifestations of Henoch-Schönlein purpura nephritis and IgA nephropathy: comparative analysis of data from the Japan Renal Biopsy Registry (J-RBR)

Lin YT A nationwide survey on epidemiological characteristics of childhood Henoch-Schönlein purpura in Taiwan

What is known about the epidemiology of the vasculitides?

Characteristics and management of IgA vasculitis (Henoch-Schönlein) in adults: data From 260 patients included in a french multicenter retrospective survey

Clinical impact of endocapillary proliferation according to the Oxford classification among adults with Henoch-Schönlein purpura nephritis: a multicenter retrospective cohort study

Henoch-Schönlein purpura in adults: outcome and prognostic factors

IgA vasculitis (Henoch-Schönlein purpura) in adults: Diagnostic and therapeutic aspects

Long-term prognosis of Henoch-Schönlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schönlein purpura

Henoch-Schönlein nephritis in adults-clinical features and outcomes in Finnish patients

Predictors of outcome in Henoch-Schönlein nephritis in children and adults

Distinct characteristics and outcomes in elderlyonset IgA vasculitis (Henoch-Schönlein purpura) with nephritis: Nationwide cohort study of data from the Japan Renal Biopsy Registry (J-RBR)

Henoch-Schönlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center

GI involvement in Henoch-Schönlein purpura

Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-2014)

Henoch-Schönlein purpura with nephritis in adults: adverse prognostic indicators in a UK population

Upper gastrointestinal bleeding as a risk factor for dialysis and all-cause mortality: a cohort study of chronic kidney disease patients in Taiwan

Using Oxford classification of IgA nephropathy to predict long-term outcomes of Henoch-Schönlein purpura nephritis in adults

Significance of histological crescent formation in patients with IgA vasculitis (Henoch-Schönlein purpura)-related nephritis: a cohort in the adult Chinese population

Early prednisone therapy in Henoch-Schönlein purpura: a randomized, double-blinded, placebo-controlled trial

A randomized, placebo-controlled trial of prednisone in early Henoch-Schönlein purpura

Clinical course of extrarenal symptoms in Henoch-Schönlein purpura: 6 6-month prospective studies

Regression Modeling Strategies: With Application to Linear Models, Logistic Regression, and Survival Analysis